Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

References:

  1. Miller et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Abstract LBA1, European Society of Medical Oncology (ESMO) Congress, Milan, October 2010.
  2. Miller et al. Phase IIb/III trial of afatinib (BIBW 2992) + best supportive care (BSC) vs. placebo + BSC in patients failing 1–2 lines of chemotherapy and erlotinib/gefitinib (LUX-Lung 1).  Oral presentation, European Society of Medical Oncology (ESMO) Congress, Milan, October 2010.
  3. Yang et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lu
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation ... to support older adults suffering from the severe ... AARP and its members are committed to helping those ... AARP and AARP Foundation will match dollar-for-dollar contributions up ... aid. The matching program will be administered through AARP ...
(Date:1/15/2014)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ... from institutional investors to purchase an aggregate of ... in an at-the-market registered direct offering, led by ... Company entered into definitive purchase agreements with these ... sell an aggregate of 3,603,603 shares of its ...
(Date:1/15/2014)... , January 15, 2014 Shire ... it has waived the Office of Fair Trading (OFT) approval ... outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... longer conditional on OFT approval, and Shire expects to complete ... scheduled expiration time, subject to the satisfaction of all of ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... For the second consecutive year, the Exergen temporal ... which stock the product, according to Nielsen and Information ... thermometers, including national brands and private label products, were ... market share has risen to 20 percent of all ...
... LLC announced today that Dr. David Hangauer, who served as ... as Chief Scientific Officer of the Company.   ... discovered and designed both of our lead compounds, KX01 and ... I have worked together with him for the last 7 ...
Cached Medicine Technology:The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer 2The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer 3
(Date:4/14/2014)... Porter Graham Child Development Institute have released their ... to prepare four-year-olds for success in kindergarten. According ... show significant gains across all areas of learning. ... greater rate during their participation in NC Pre-K ... scientist Ellen Peisner-Feinberg, who leads the FPG team ...
(Date:4/14/2014)... children with uncomplicated acute appendicitis is a reasonable alternative ... missed school days, according to a pilot study. The ... and published online April 12 in the Journal ... first prospective study on nonoperative management of acute appendicitis ... Researchers enrolled 77 patients age 7 to 17 who ...
(Date:4/14/2014)... shows that domestic abuse is closely linked to ... stress disorder (PTSD), in mothers. The research also ... with specific mental health problems. The work was ... Simon Fraser University and the University of British ... how intimate partner abuse physical, psychological and ...
(Date:4/13/2014)... program for adolescent girls in Kenyan slums sharply ... who live in an environment where women have ... new study shows. , The findings, by researchers ... Packard Children,s Hospital Stanford and the nongovernmental organization ... in combating an appallingly common hazard among girls ...
(Date:4/11/2014)... a severe disease for which there is still no ... what happens in the brain of a schizophrenic person, ... proteins in the brains of rats that have been ... new and better medicines. , Seven per cent of ... have tried for centuries to understand the disease, they ...
Breaking Medicine News(10 mins):Health News:Study gives high marks to NC Pre-K program 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Study links domestic abuse to mental health problems in new mothers 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4Health News:Protein researches closing in on the mystery of schizophrenia 2Health News:Protein researches closing in on the mystery of schizophrenia 3
... that one in three early-stage breast cancer patients who ... they did not fully understand their discussions with physicians ... About one in four experienced distress when receiving their ... a peer-reviewed journal of the American Cancer Society, the ...
... Scientists at the Stanford University School of Medicine have ... device to virtually separate a whole-blood sample into its different ... any one of those cell types. In a study ... , the scientists reported that they had successfully used the ...
... that much harder to eliminate, scientists say , SUNDAY, March ... the AIDS virus in the blood to zero, but HIV ... their pills. Now, research is giving scientists new insight into ... powers of medicine. , In a new study, researchers ...
... ... Medicine residents in hypertension therapy and sleep disorders will receive international recognition at the ... ... the work of two St. Elizabeth Internal Medicine residents in hypertension therapy and sleep ...
... ... certification. Their revolutionary line of quick couplings and plastic fittings are all designed, ... ... -- Kent Systems received their Made in the USA Brand certification. Their revolutionary ...
... The Pediatric Cancer ... Annual “Reaching for the Cure” 10K Run, 5K Run/Walk, and 1K Kids’ Fun Run ... Irvine, CA (PRWEB) March 7, ... “Reaching for the Cure” Half Marathon | 10K 5K Run | 5K Walk | ...
Cached Medicine News:Health News:Improvements needed in genomic test result discussions 2Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 2Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 3Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 4Health News:HIV Hides Out in Bone Marrow Cells 2Health News:St. Elizabeth Medical Residents to Present Research at International Meeting, 2Health News:Kent Systems Received Made in the USA Brand Certification 2Health News:Sponsors for the 2010 Pediatric Cancer Research Foundation “Reaching for the Cure” Annual Cinco de Mayo Run/Walk Fundraising Event 2Health News:Sponsors for the 2010 Pediatric Cancer Research Foundation “Reaching for the Cure” Annual Cinco de Mayo Run/Walk Fundraising Event 3
The GE e-Speed™scanner, the worlds fastest computed tomography (CT) imaging platform, delivers a new advanced tool for physicians to see and diagnose heart disease....
...
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless ...
16mm Slightly Curved sharp Tips; overall length 120mm; Stainless Steel...
Medicine Products: